Clinical trials: Investigation Time
Pain
Evaluate the Depth and Duration of Anesthesia
The purpose of the study is to determine the depth (mm) of anesthesia provided by the Synera topical patch (using sensory depth and pain depth evaluations), and to determine the duration (minutes) of anesthesia provided by the…
- Trial name
- NCT00891163
- Testing
- Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- ZARS Pharma Inc.
Vestibular Migraine
The Effect of Bone-Conducted Stimulation on Rotary Chair Time Constants in Patients With Vestibular Migraines
The goal of this clinical trial is to learn if the Otolith Labs device can improve vestibular function of subjects with vestibular migraine.
- Trial name
- VIBRANT-VM (NCT06540235)
- Testing
- Otolith Device Active, Otolith Device Inactive
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Otolith Labs
Acute Blunt Soft Tissue Injuries/Contusions
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries
This study will assess the analgesic efficacy of DSG 1% compared to placebo in the reduction of the pain associated with acute blunt trauma injuries.
- Trial name
- NCT02290821
- Where
- 10 sites in United States
- Volunteers
- 215 people
- Sponsor
- Novartis
Type 2 Diabetes, T2D
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose escalation compared to insulin glargine in adults with type 2 diabetes (T2D) who…
- Trial name
- QWINT-1 (NCT05662332)
- Testing
- Insulin Efsitora Alfa, Insulin Glargine
- Where
- 71 sites in United States, Argentina and 2 more
- Volunteers
- 795 people
- Sponsor
- Eli Lilly and Company
PAIN
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340
The purpose of this study in healthy people is to evaluate safety, toleration and time course of plasma concentration of single oral doses of PF-06273340.
- Trial name
- NCT01601834
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Rotavirus
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants
This Post Marketing Surveillance (PMS) will collect reactogenicity and safety data on the use of human rotavirus vaccine in healthy infants aged from 6 weeks (first dose) to not more than 24 weeks (second dose).
- Trial name
- NCT00779779
- Testing
- Rotarix™
- Where
- Sri Lanka
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Renal Artery Stenosis
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
The study will evaluate the efficacy and safety of Dotarem enhanced MRA compared to TOF MRA in patients suffering from renal arterial disease.
- Trial name
- NCT00845702
- Testing
- Gadoterate meglumine (Dotarem), Time of Flight Magnetic Resonance Angiography
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Guerbet
Coronary Artery Disease
Phase 3 Imaging and Safety Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing SPECT Imaging
This study was designed to evaluate the ability of AI-700-enhanced rest-stress echocardiography to detect coronary artery disease (CAD) in patients with suspected ischemic heart disease who are indicated for single-photon…
- Trial name
- NCT00156793
- Testing
- AI-700 contrast-enhanced echocardiography
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Acusphere
Pain, Inflammatory
First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160.
This is a first-time-in-human study. The overall purpose of the study is to assess whether the drug is safe and well tolerated after single, increasing doses.
- Trial name
- NCT00849134
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071
This study will evaluate the safety and tolerability of ascending single oral doses greater than 500 mg of AEB071 in healthy subjects
- Trial name
- NCT00409929
- Testing
- AEB071
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novartis
Obesity
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected)…
- Trial name
- NCT07225816
- Testing
- Liraglutide, Oral Semaglutide, Semaglutide
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with…
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck
- Trial name
- NCT04504669
- Testing
- AZD8701, Durvalumab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Oral Mucositis, Quality of Life
Retrospective Observational Study of Oral Complications and Quality of Life in Head and Neck Cancer Patients Treated With Radiotherapy or Chemoradiotherapy.
Head and Neck cancer patients receiving radiation therapy (with or without chemotherapy) suffer several oral complications, such as oral mucositis, which impairs quality of life of patients during radiotherapy and in the…
- Conditions
- Oral Mucositis, Quality of Life, Mucositis, Pain
- Trial name
- NCT07739771
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Mucosa Innovations, S.L.
Impotence
Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction
Assessment of duration of action, safety \& toleration of different formulations and doses of UK-369,003 and Cialis in patients with male erectile dysfunction.
- Trial name
- NCT00174486
- Testing
- UK0369,003, Cialis (Tadalafil)
- Volunteers
- 300 people
- Sponsor
- Pfizer
Pupil Constriction
Evaluation of NV701 (Pilocarpine 1.25%) Compared With Vuity (Pilocarpine 1.25%) on Pupil Size in Subjects With Presbyopia
Randomized contralateral eye study to evaluate the effect of one-time dosing of NV701 versus commercially available 1.25% pilocarpine solution on pupil size.
- Trial name
- NCT06783686
- Testing
- NV701, Pilocarpine 1.25% Eye drop
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novus Vision LLC
Arthroplasty, Replacement, Prevention of Venous Thromboembolism
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip…
- Conditions
- Arthroplasty, Replacement, Prevention of Venous Thromboembolism, Moderate Renal Impairment (CrCl 30-50 mL/Min)
- Trial name
- NCT01184989
- Testing
- Dabigatran etexilate
- Where
- 10 sites in Austria, Canada and 4 more
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder
Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology
The purpose of this study was to evaluate the feasibility and compliance with a novel method for assessing mood and cognition in participants with major depressive disorder (MDD).
- Trial name
- NCT03067506
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Takeda
Symptom Assessment
ESSENCE is a Quality Improvement Study That Evaluates the Impact of Ada's AI-powered Core Symptom Assessment Technology on Clinical Workflow and Individual Healthcare Guidance, Following the November 2021 Integration of the Tool Into the CUF Hospital Network. Study Duration Nov 2024-Oct 2025
A 1.5.1 Study title ESSENCE Study: E-health Self Symptom assEssmeNt as a front door and facilitator of CarE A 1.5.2 Investigational device 'Ada Assess' (CE-marked), 'Ada Connect' (a software integrating with CE-marked medical…
- Trial name
- ESSENCE (NCT06846957)
- Where
- Portugal
- Volunteers
- 1,470 people
- Sponsor
- Ada Health GmbH
Colitis, Ulcerative
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
"GSK4528287 is a drug being developed to treat like inflammatory bowel diseases like Crohns disease and ulcerative colitis. This study is the first time that GSK4528287 will be given to humans.
- Trial name
- NCT06681181
- Testing
- GSK4528287
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma
This study is conducted to assess whether training participants on proper use of BF SPIROMAX and Symbicort TURBOHALER will improve their device-handling technique and potentially improve their treatment outcome, that is, better…
- Trial name
- ELIOT (NCT02062463)
- Testing
- Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX, SYMBICORT TURBOHALER budesonide and formoterol fumarate
- Where
- 74 sites in United Kingdom
- Volunteers
- 485 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.